Wall Street brokerages expect that Horizon Pharma PLC (NASDAQ:HZNP) will post sales of $245.18 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Horizon Pharma’s earnings. The highest sales estimate is $257.00 million and the lowest is $233.35 million. Horizon Pharma reported sales of $220.86 million in the same quarter last year, which indicates a positive year-over-year growth rate of 11%. The firm is scheduled to issue its next earnings results on Monday, May 14th.
On average, analysts expect that Horizon Pharma will report full year sales of $245.18 million for the current financial year, with estimates ranging from $1.15 billion to $1.17 billion. For the next fiscal year, analysts expect that the business will post sales of $1.25 billion per share, with estimates ranging from $1.19 billion to $1.30 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Horizon Pharma.
Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.07. Horizon Pharma had a positive return on equity of 18.44% and a negative net margin of 38.87%. The company had revenue of $274.22 million during the quarter, compared to analysts’ expectations of $264.48 million. During the same period last year, the firm posted $0.64 earnings per share. The business’s revenue was down 11.6% on a year-over-year basis.
A number of analysts have recently issued reports on HZNP shares. BidaskClub raised Horizon Pharma from a “hold” rating to a “buy” rating in a research report on Friday, December 22nd. Cantor Fitzgerald set a $17.00 target price on Horizon Pharma and gave the stock a “buy” rating in a research note on Wednesday, December 27th. ValuEngine lowered Horizon Pharma from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Mizuho upgraded Horizon Pharma from a “neutral” rating to a “buy” rating and increased their target price for the stock from $12.00 to $18.00 in a research note on Friday, January 12th. Finally, UBS set a $20.00 target price on Horizon Pharma and gave the stock a “buy” rating in a research note on Thursday, March 1st. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. Horizon Pharma has an average rating of “Buy” and an average target price of $18.64.
Several hedge funds and other institutional investors have recently made changes to their positions in HZNP. William Blair Investment Management LLC increased its stake in Horizon Pharma by 12.2% during the 4th quarter. William Blair Investment Management LLC now owns 8,826,079 shares of the biopharmaceutical company’s stock worth $128,861,000 after acquiring an additional 958,414 shares during the period. Sterling Capital Management LLC bought a new position in Horizon Pharma during the 4th quarter worth $1,340,000. Segall Bryant & Hamill LLC increased its stake in Horizon Pharma by 12.6% during the 4th quarter. Segall Bryant & Hamill LLC now owns 725,002 shares of the biopharmaceutical company’s stock worth $10,585,000 after acquiring an additional 81,074 shares during the period. Redmile Group LLC bought a new position in Horizon Pharma during the 4th quarter worth $292,000. Finally, Cowen Inc. bought a new position in Horizon Pharma during the 4th quarter worth $781,000. Institutional investors own 86.54% of the company’s stock.
Shares of HZNP traded down $0.01 during mid-day trading on Monday, reaching $13.64. The company’s stock had a trading volume of 1,623,705 shares, compared to its average volume of 1,856,142. Horizon Pharma has a 1-year low of $9.45 and a 1-year high of $16.02. The stock has a market cap of $2,251.92, a price-to-earnings ratio of 11.56, a PEG ratio of 0.58 and a beta of 1.24. The company has a quick ratio of 1.54, a current ratio of 1.63 and a debt-to-equity ratio of 1.91.
TRADEMARK VIOLATION NOTICE: “Horizon Pharma PLC (HZNP) Expected to Post Quarterly Sales of $245.18 Million” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/04/09/horizon-pharma-plc-hznp-expected-to-post-quarterly-sales-of-245-18-million.html.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Get a free copy of the Zacks research report on Horizon Pharma (HZNP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.